The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Interleukin‐29 uses a type 1 interferon‐like program to promote antiviral responses in human hepatocytes†
Abstract
Interleukin-28A (IL-28A), IL-28B and IL-29 are a family of class II cytokines that stimulate antiviral responses through a heterodimeric receptor that is distinct from the type I interferon (IFN) receptor. To better understand how this newly described family of cytokines regulates the antiviral state, we compared various cellular responses elicited by IL-29 and IFN-alpha. Here we show that these cytokines stimulate similar patterns of signal transducer and activator of transcription 1 (STAT-1), -2, -3, and -5 phosphorylation and nearly identical patterns of gene expression when analyzed in two distinct cell types by microarray analysis. Interestingly, the IL-29 receptor is preferentially expressed on primary hepatocytes within normal liver and pegylated forms of IL-29 and IFN-alpha induced equivalent 2'5' oligoadenylate synthetase (OAS) and MX1 gene expression in this cell type. Pegylated IL-29 also produced a significant reduction in human hepatitis B and hepatitis C viral load in vitro and reduced the cytopathic effect caused by the fully replicating flavivirus, West Nile virus. In conclusion, IL-29 and IFN-alpha stimulate identical antiviral responses despite their utilization of different receptors. This fact, combined with significant receptor expression in hepatitis virus-infected livers, suggests that IL-29 may have therapeutic value against chronic viral hepatitis in human patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Lauer, G. M., & Walker, B. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450107 · Cited by 2,973
Antiviral Actions of Interferons
Samuel, C. E. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.778-809.2001 · Cited by 2,743
IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex
Kotenko, S. V., Gallagher, G., Baurin, V. V., Lewis-Antes, A., Shen, M., Shah, N. K., Langer, J. A., Sheikh, F., Dickensheets, H., & Donnelly, R. P. (2003) · Nature Immunology · doi:10.1038/ni875 · Cited by 1,868
Interferons, interferon‐like cytokines, and their receptors
Pestka, S., Krause, C. D., & Walter, M. R. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00204.x · Cited by 1,766
Panahi, M., Naderi, M., Morteza, T. S., & Parizadeh, S. M. J. (2007) · Cited by 1,722
Cited by
Regulation and Functions of the IL-10 Family of Cytokines in Inflammation and Disease
Ouyang, W., Rutz, S., Crellin, N. K., Valdez, P. A., & Hymowitz, S. G. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101312 · Cited by 1,925
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Study, F. T. H. C., Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., Bassendine, M., Spengler, U., Dore, G. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.447 · Cited by 1,826
Shared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
The immunogenetics of Psoriasis: A comprehensive review
Harden, J. L., Krueger, J. G., & Bowcock, A. M. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.07.008 · Cited by 616
Interferon-λ: Immune Functions at Barrier Surfaces and Beyond
Lazear, H. M., Nice, T. J., & Diamond, M. S. (2015) · Immunity · doi:10.1016/j.immuni.2015.07.001 · Cited by 480
Zhou, Z., Hamming, O. J., Ank, N., Paludan, S. R., Nielsen, A. L., & Hartmann, R. (2007) · Journal of Virology · doi:10.1128/jvi.02438-06 · Cited by 479
Interferon-Lambda: A New Addition to an Old Family
Donnelly, R. P., & Kotenko, S. V. (2010) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0078 · Cited by 420
An Important Role for Type III Interferon (IFN-λ/IL-28) in TLR-Induced Antiviral Activity
Ank, N., Iversen, M. B., Bartholdy, C., Staeheli, P., Hartmann, R., Jensen, U. B., Dagnaes-Hansen, F., Thomsen, A. R., Chen, Z., Haugen, H., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2474 · Cited by 419
Self-citationGuarding the frontiers: the biology of type III interferons
Wack, A., Terczyńska-Dyla, E., & Hartmann, R. (2015) · Nature Immunology · doi:10.1038/ni.3212 · Cited by 364
Induction and function of type I and III interferon in response to viral infection
Levy, D. E., Marié, I. J., & Durbin, J. E. (2011) · Current Opinion in Virology · doi:10.1016/j.coviro.2011.11.001 · Cited by 314
Hernández, P. P., Mahlakõiv, T., Yang, I., Schwierzeck, V., Nguyen, N., Guendel, F., Gronke, K., Ryffel, B., Hölscher, C., Dumoutier, L., et al. (2015) · Nature Immunology · doi:10.1038/ni.3180 · Cited by 287
Interferon-λ orchestrates innate and adaptive mucosal immune responses
Ye, L., Schnepf, D., & Staeheli, P. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0182-z · Cited by 266
Type I interferons: crucial participants in disease amplification in autoimmunity
Hall, J. C., & Rosen, A. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.237 · Cited by 265
INTERFEROME: the database of interferon regulated genes
Samarajiwa, S. A., Forster, S., Auchettl, K., & Hertzog, P. J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn732 · Cited by 265
Lambda Interferon Is the Predominant Interferon Induced by Influenza A Virus Infection In Vivo
Jewell, N. A., Cline, T., Mertz, S. E., Smirnov, S. V., Flaño, E., Schindler, C., Grieves, J. L., Durbin, R. K., Kotenko, S. V., & Durbin, J. E. (2010) · Journal of Virology · doi:10.1128/jvi.01703-09 · Cited by 263
IL-28 and IL-29: Newcomers to the interferon family
Uzé, G., & Monneron, D. (2007) · Biochimie · doi:10.1016/j.biochi.2007.01.008 · Cited by 260
Aggad, D., Mazel, M., Boudinot, P., Mogensen, K. E., Hamming, O. J., Hartmann, R., Kotenko, S., Herbomel, P., Lutfalla, G., & Levraud, J.-P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901495 · Cited by 257
Interferons: Success in anti-viral immunotherapy
Lin, F.-C., & Young, H. A. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.015 · Cited by 254
Interferon-λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier
Lazear, H. M., Daniels, B. P., Pinto, A. K., Huang, A. C., Vick, S. C., Doyle, S. E., Gale, M., Klein, R. S., & Diamond, M. S. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4304 · Cited by 234
Self-citation
Metadata
- Authors
- Doyle, S. E., Schreckhise, H., Khuu‐Duong, K., Henderson, K., Rosler, R., Storey, H., Yao, L., Liu, H., Barahmand‐pour, F., Sivakumar, P., Chan, C., Birks, C., Foster, D., Clegg, C. H., Wietzke‐Braun, P., Mihm, S., & Klucher, K. M.
- Venue
- Hepatology
- Published
- 2006-10
- Volume
- 44
- Issue
- 4
- Pages
- 896-906
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2068931925
- Cited by
- 348
- References
- 37
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.